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Background. Human herpesvirus– 8 (HHV-8) replication is critical in the induction and maintenance of Kaposi
sarcoma, primary effusion lymphoma, and some cases of Castleman disease. In vitro and observational studies suggest
that ganciclovir inhibits HHV-8 replication, but no randomized clinical trials have been conducted.
Methods. A total of 26 men infected with HHV-8 were randomized to receive 8 weeks of valganciclovir admin-
istered orally (900 mg once per day) or 8 weeks of placebo administered orally. After a 2-week washout period,
participants in each group received the study drug they had not yet taken (either valganciclovir or placebo), for 8
additional weeks. Oral swab samples were collected daily during the study, and HHV-8 and CMV DNA were quan-
tified by real-time PCR.
Results. A total of 16 human immunodeficiency virus (HIV)–positive men and 10 HIV-negative men enrolled in
and completed the study. Of the 3439 swab samples that participants had been expected to provide, 3029 (88%) were
available for analysis. HHV-8 was detected on 44% of swabs collected from participants who were receiving placebo,
compared with 23% of swabs collected from participants who were receiving valganciclovir (relative risk [RR], 0.54
[95% confidence interval {CI}, 0.33– 0.90]; P  .02). Valganciclovir reduced oropharyngeal shedding of cytomega-
lovirus by 80% (RR, 0.20 [95% CI, 0.08 – 0.48];P  .001). Shedding of HHV-8 and shedding of cytomegalovirus were
independent. Hematologic, renal, or hepatic toxicities were no more common among participants who received the
active drug, compared with those who received placebo, though participants who received valganciclovir reported
more days of diarrhea.
Conclusions. Valganciclovir administered orally once per day is well tolerated and significantly reduces the
frequency and quantity of HHV-8 replication.
Human herpesvirus– 8 (HHV-8) is the etiologic agent of
Kaposi sarcoma (KS), primary effusion lymphoma
(PEL), and multicentric Castleman disease (MCD) [1].
Although the incidence of KS has declined where the use
of highly active antiretroviral therapy (HAART) is wide-
spread [2], it remains the most common AIDS-
associated malignancy in the United States [3], as well as
the primary malignancy following transplantation in
some geographic regions [4] and the most common can-
cer throughout the population in many parts of Africa
[5]. The response of KS to treatment with chemotherapy
or HAART is often incomplete [6], and no therapy for
MCD or PEL has been proven effective in comparative
trials.
The study of antiviral therapy for HHV-8 infection
has been hampered by the lack of a traditional in vitro
system to model HHV-8 replication. The virus does not
sustain lytic replication in cell culture, which prohibits
the use of antiviral susceptibility testing methods that
rely on cytopathic effect, and no animal model of
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HHV-8 infection has been established. The in vitro susceptibility
of HHV-8 to antiviral drugs has been supported by 2 findings.
First, ganciclovir is phosphorylated in the presence of both the
HHV-8 thymidine kinase at open reading frame (ORF) 21 and
phosphotransferase at ORF36 [7]. Second, ganciclovir, cidofo-
vir, and foscarnet inhibit the production of HHV-8 from latently
infected cell lines upon stimulation, whereas antiviral medica-
tions such as acyclovir have been shown to have little or no ac-
tivity against HHV-8 [8 –12]. These preclinical studies offer
strong support for the antiviral activity of valganciclovir against
HHV-8.
We hypothesized that valganciclovir will reduce HHV-8 rep-
lication in vivo. Ganciclovir therapy reduces the symptoms and
signs of HHV-8 –associated MCD in parallel with reductions of
the HHV-8 load in plasma [13]. Early observations made during
studies of ganciclovir therapy for cytomegalovirus (CMV) reti-
nitis in HIV-positive patients found that ganciclovir reduced the
rate of new KS development; the reduction was found to range
from 40%, by Mocroft et al. [14], to 75%, by Martin et al. [15].
These studies suggest that inhibition of HHV-8 replication may
be associated with clinical benefit, but data on HHV-8 replica-
tion were not collected. Additionally, HHV-8 replication may be
activated by CMV [16], so it remains unclear whether the effect
of ganciclovir on KS that has been observed in prior trials was a
direct result of antiviral activity against HHV-8 or an indirect
result of ganciclovir’s suppression of CMV replication. To date,
no randomized clinical trial has assessed the effect of antiviral
medication on HHV-8 replication.
Replicating HHV-8 is found most frequently in the orophar-
ynx, and the daily collection of saliva for the quantification of
HHV-8 DNA provides a simple and accurate measure of the
level of HHV-8 replication [17, 18]. We therefore sought to de-
termine the safety and efficacy of valganciclovir on HHV-8 rep-
lication in the oropharynx in HIV-seropositive and HIV-
negative persons who were asymptomatically infected with
HHV-8, by use of a randomized, double-blind, placebo-
controlled, crossover trial.
METHODS
Study participants. To define the potential antiviral effects of
valganciclovir on HHV-8 replication, we selected 26 men for this
study who had been observed in previous trials to shed HHV-8
from the oropharynx on40% of the days their saliva was sam-
pled [18]. Subjects were recruited at the University of Washing-
ton Virology Research Clinic in Seattle between February 2003
and February 2005. Persons receiving medications known to
have activity against human herpesviruses or who were known
to have bone marrow suppression, a history of CMV disease,
hypersensitivity to ganciclovir, or evidence of renal or hepatic
dysfunction were excluded. Participants were eligible regardless
of their HIV infection status, but HIV-positive participants who
were receiving antiretroviral therapy (ART) could not change
medications during the course of the study. The first 26 men who
agreed to participate and who met the inclusion criteria were
enrolled in the study.
Study procedures. On enrollment, participants were ran-
domly assigned to initially receive either valganciclovir or pla-
cebo, 900 mg administered orally once per day for 8 weeks (fig-
ure 1). Participants were randomized by use of a computerized
random number generator and stratified by HIV status. Partic-
ipants, clinicians, laboratory personnel, and biostatisticians were
blinded to treatment assignment throughout the trial. After a
2-week washout period during which no study medications were
taken, participants then received the other treatment for another
8 weeks. Participants collected oropharyngeal swab samples
daily and kept a symptom diary at home, as described elsewhere
[18]. The diary surveyed common gastrointestinal complaints
(nausea, vomiting, diarrhea, abdominal pain, and cramping)
and constitutional symptoms (fever, night sweats, chills, and
swollen glands), as well as sore throat, rash, headache, days
missed from school or work, and visits to health-care profession-
als. Participants returned to clinic every 2 weeks for tests to assess
drug safety (i.e., a complete blood count with differential, he-
patic, and renal function tests), ascertainment of adherence to
medication schedule by use of pill counts, and return of oropha-
ryngeal swab samples. A data safety monitoring board reviewed
all clinical and laboratory data when 50% of participants had
completed the first arm of the study.
Laboratory assessments. Serum samples were tested for an-
tibodies to HIV and CMV by use of enzyme immunoassays (Ab-
Figure 1. Study design for a trial of valganciclovir involving 26 par-
ticipants asymptomatically infected with human herpesvirus–8.
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bott Laboratories). DNA was extracted from oropharyngeal
swab samples for the quantification of HHV-8 by real-time poly-
merase chain reaction (PCR) using primers to orf73 [19], and for
the quantification of CMV with a double-primer set to UL55 and
UL123-exon 4 [20]. All samples with 500 copies of HHV-8
DNA/mL or100 copies of CMV DNA/mL were characterized
as positive [18, 20]. Several negative and positive controls were
run with each reaction, including 2 reaction mixtures without
DNA (negative controls) and at least 1 sample with a known
quantity of HHV-8 DNA. An internal control was amplified with
each specimen to assure that negative results were not attribut-
able to inhibition of PCR [18, 20]. Specimens were run in
batches of 560 swabs. They were grouped into these batches on
the basis of when the specimens were received in the lab. Most
participants submitted 14 days of swab samples at a visit; conse-
quently, each run typically contained a mix of participants from
both the active treatment and placebo arms of the trial.
Statistical analysis. The primary end point was the reduc-
tion in oropharyngeal replication of HHV-8 associated with val-
ganciclovir use, as measured by HHV-8 shedding frequency,
which was defined by the number of days on which HHV-8 was
detected in samples analyzed by PCR divided by the total num-
ber of days for which samples were analyzed by PCR. The sec-
ondary end point was the safety of valganciclovir in persons with
asymptomatic HHV-8 infection. In this crossover study design,
each person acted as their own control to minimize the effect of
variability in HHV-8 shedding rate on treatment efficacy mea-
sures and to optimize study power. Assuming a background
shedding rate of 40% and allowing for a 20% dropout rate, we
calculated that 26 participants would be required for the study to
have an 80% chance of detecting a50% reduction in the rate of
detection of HHV-8 in the oropharynx.
All data were collected and managed at the University of
Washington and categorized and initially analyzed without
knowledge of the participants’ treatment assignment. The first
day of that a participant received either valganciclovir or placebo
and the days of the washout period were excluded from treat-
ment efficacy analyses. Generalized linear mixed models using
the Poisson distribution and log link with person-level random
effects were used to test the efficacy of valganciclovir in reducing
the frequency of HHV-8 and CMV replication. The quantity of
HHV-8 was analyzed for days on which HHV-8 was detected,
and the quantity was log10 transformed prior to analysis. Linear
mixed effects models with person-level random intercepts com-
pared the mean quantity of HHV-8 detected in participants in
the active treatment arm and the placebo arm. Covariates for
time period and the interaction between time period and treat-
ment were created to test for period and carryover effects [21].
To summarize both frequency and quantity data graphically, the
mean log10 copies per milliliter of HHV-8 DNA detected was
calculated by using all days, assigning the value 0 to days on
which HHV-8 was not detected.
Safety was monitored by clinical and laboratory evaluation of
the participants. Transaminitis was defined by a serum alanine
aminotransferase level 250 U/dL, renal insufficiency was de-
fined by a serum creatinine level 1.5 mg/dL, anemia was de-
fined by a hematocrit30%, thrombocytopenia was defined by
a platelet count of 20,000 cells/mL, and neutropenia was de-
fined by a neutrophil count of 1500 cells/mL. Person-level
comparisons of adverse events in participants who received ac-
tive drug and practicableness who received placebo used McNe-
mar’s test, and day-level comparisons of adverse events used
generalized linear mixed effects models. SAS statistical software
(version 9.1; SAS Institute) was used for all analyses.
Adherence rates, calculated as the number of unreturned pills
divided by the total pills each participant should have taken,
were compared between active treatment and placebo arms by
using generalized linear mixed models. The Spearman rank cor-
relation coefficient was used to estimate the correlation between
adherence rates and treatment efficacy, as well as the relationship
between treatment efficacy for HHV-8 and CMV.
RESULTS
Participant characteristics. The median age of study partici-
pants was 42 years (range, 24 – 66 years), and 17 (65%) of 26
participants reported their race as white (table 1). All partici-
pants identified themselves as men who have sex with men. Six-
teen (62%) of 26 participants were HIV-positive, with a median
CD4 T cell count of 434 cells/mm3 (range, 49 –936 cells/mm3)
and a mean HIV RNA plasma level of log10 3.8 copies/mL (range,
2.2–5.3 copies/mL). Eight (50%) of 16 HIV-positive participants
were receiving ART during the course of the study, including 7
who were receiving HAART, which was defined as any combi-
nation of 3 antiretroviral agents that included at least 1 non-
nucleoside reverse transcriptase or protease inhibitor.
Effect of valganciclovir on the detection of HHV-8 in the
oropharynx. Of 3439 oropharyngeal swab samples that partic-
ipants had been expected to provide, 3029 (88%) were available
for analysis. Valganciclovir reduced the frequency with which
HHV-8 was detected in saliva as well as the quantity detected.
HHV-8 was detected on 583 (44%) of 1333 days among patients
who were receiving placebo and on 318 (23%) of 1360 days
among patients who were receiving valganciclovir Thus, the use
of valganciclovir was associated with a 46% reduction in the
frequency with which HHV-8 was detected in the oropharynx,
with a relative risk (RR) of 0.54 for the detection of HHV-8
during administration of valganciclovir, compared with placebo
(95% confidence interval [CI], 0.33– 0.90; P  .02).
Next, we analyzed the quantity of HHV-8 detected in the oro-
pharynx on the days on which HHV-8 was detected. The mean
log10 copies per milliliter detected for participants who were re-
ceiving placebo was 5.0 copies/mL (range, 2.7–7.9 copies/mL),
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compared with 4.7 copies/mL for participants who were receiv-
ing valganciclovir (range, 2.7–7.6 copies/mL). Valganciclovir
significantly reduced the quantity of HHV-8 by 0.44 logs (95%
CI, 0.12– 0.75 logs; P  .007).
Reductions in oropharyngeal shedding of HHV-8 were seen
among both HIV-positive and HIV-negative participants.
Person-level comparison showed that 15 (94%) of 16 HIV-
positive participants had HHV-8 detected on at least 1 day dur-
ing the time they were receiving placebo, compared with 11
(69%) of 16 HIV-positive participants during time they were
receiving valganciclovir. We also observed a reduction in day-
level rates of HHV-8 detection in HIV-positive participants,
with HHV-8 detected on 438 (53%) of 822 days during the time
these participants received placebo versus 246 (29%) of 854 days
during the time they received valganciclovir. Among HIV-
negative participants, 9 (90%) of 10 had HHV-8 detected in sa-
liva on at least 1 day during the time they received placebo versus
8 (80%) of 10 during the time they received valganciclovir. How-
ever, for the HIV-negative subgroup, HHV-8 was detected on
145 (28%) of 511 days during placebo use versus 72 (14%) of 506
days during valganciclovir use.
Analyses that adjusted for HIV and HAART status showed
that receipt of valganciclovir significantly reduced the risk of
HHV- 8 being detected in the oropharynx, by 46% (RR, 0.54
[95% CI, 0.33– 0.90]; P  .02), and it reduced the HHV-8 DNA
copy number by a mean of 0.44 logs (95% CI, 0.12 to 0.76 logs;
P  .007) (table 2). Small numbers of participants precluded
detailed analyses of the effect of valganciclovir in subgroups de-
fined by HIV infection status and HAART use, but modeling
suggested differential effects of valganciclovir within HIV and
HAART categories (P  .053 for interaction), with the greatest
treatment effect occurring among the HIV-positive participants
who were receiving HAART (RR, 0.30 [95% CI, 0.19 – 0.47];
P  .001).
In analyses that adjusted for valganciclovir use, HIV-positive
participants who were not receiving HAART (RR, 2.36 [95% CI,
Table 1. Demographic and clinical baseline characteristics of 26 participants asymptomatically
infected with human herpesvirus–8.
Characteristic
HIV infection status
Total
(n  26)
Negative
(n  10)
Positive
(n  16)
Age, median (range), years 45 (37–66) 40 (24–54) 42 (24–66)
Race or ethnicity
White 8 (80) 9 (56) 17 (65)
Non-white 2 (20) 7 (44) 9 (35)
CMV infection status
Positive 9 (90) 16 (100) 25 (96)
Negative 1 (10) 0 (0) 1 (4)
CD4 T lymphocyte count, median (range), cells/mm3 NA 434 (49–93) NA
Plasma HIV RNA level, mean (range), log10 copies/mL NA 3.8 (2.2–53) NA
Receipt of antiretroviral drugs
None NA 8 (50) NA
Non-HAART NA 1 (6) NA
HAART NA 7 (44) NA
NOTE. Data are no. (%) of participants, unless otherwise indicated. CMV, cytomegalovirus; HAART, highly active
antiretroviral therapy; NA, not applicable.
Table 2. Effect of valganciclovir on the frequency and quantity of oropharyngeal shedding of human herpesvi-
rus–8 (HHV-8).
Outcome measure
Study arm
Estimated measure
of effecta (95% CI) PPlacebo Valganciclovir
Days on which HHV-8 was detected
in saliva, proportion (%) 583/1333 (44) 318 /1360 (23) Relative risk, 0.54 (0.33 to 0.90) .02
Quantity of HHV-8 in saliva (range),
mean log10 copies/mL b 5.0 (2.7–7.9) 4.7 (2.7–7.6) Coefficient, 0.44 (0.76 to 0.12) .007
NOTE. CI, confidence interval.
a Adjusted for treatment arm, HIV infection status, and use of highly active antiretroviral therapy.
b Calculated only for days during which HHV-8 was detected in saliva.
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1.00 –5.53]) and those who were receiving HAART (RR, 1.59
[95% CI, 0.58 – 4.34]) tended to shed HHV-8 more frequently
than HIV-negative men, although this comparison was not sta-
tistically significant overall (P  .14). HHV-8 shedding was
more common among HIV-positive persons with higher CD4 T
cell counts (RR, 6.0 for participants with CD4 cell count 200
cells/mm3 vs. 200 cells/mm3 [95% CI, 2.0 –17.7]; P  .003).
The effect of valganciclovir on the quantity of HHV-8 did not
vary greatly by HIV infection status or HAART use (P  .98 for
interaction).
Kinetics of HHV-8 inhibition with valganciclovir. During
the time participants received valganciclovir, minimal HHV-8
shedding (10%) was observed in approximately half of the par-
ticipants (figure 2). On average, lower levels of HHV-8 shedding
were observed after the first 1–2 weeks of valganciclovir treatment
(figure 3). As participants switched to the washout period and re-
ceipt of placebo, the frequency and amount of viral shedding re-
bounded. We did not find significant period effects (i.e., the effect of
valganciclovir was the same whether it was given before or after
placebo) or carryover effects (i.e., treatment with valganciclovir first
did not affect shedding in patients who subsequently received pla-
cebo) for either the frequency of shedding (P  .83 and P  .76,
respectively) or the quantity of shedding (P  .90 and P  .59,
respectively) (figure 3A compared with 3B).
Effect of valganciclovir on CMV replication and relation to
HHV-8 replication. Twenty five (96%) of 26 men were sero-
positive for CMV, and 14 (56%) shed CMV from the orophar-
ynx on at least 1 day of the study (9 HIV-positive participants
and 5 HIV-negative participants). Valganciclovir reduced CMV
shedding by 80%, compared with shedding among participants
who were not receiving the drug (RR, 0.20 [95% CI, 0.08 – 0.48];
P  .001); CMV was detected on 163 (13%) of 1255 days that
placebo was used, compared with 33 (3%) of 1215 days that
valganciclovir was used. Valganciclovir’s effect on CMV was
seen in both HIV-positive participants (109 [14%] of 798 days of
placebo use vs. 23 [3%] of 821 days of valganciclovir use with
CMV-positive samples) and HIV-negative participants (54
[12%] of 457 days of placebo use vs. 10 [3%] of 394 days of
valganciclovir use with CMV-positive samples).
Among the 11 participants who were never observed to shed
CMV, valganciclovir still reduced HHV-8 shedding (56% shed-
ding rate during placebo use vs. 29% shedding rate during val-
ganciclovir use [RR, 0.53 {95% CI, 0.29 – 0.97}; P  .04]). We
found no significant correlation between the effect of valganci-
clovir on HHV-8 and the effect of valganciclovir on CMV
(r  0.15; P  .47).
Adherence to medication regimen and safety of valganciclovir.
Of 5560 pills, 5274 (94.9%) were not returned, yielding an esti-
mated median adherence rate of 97.1% (range, 73%–100%). Ad-
herence rates were not significantly different during the time par-
ticipants received placebo arm and the time they received active
drug (P  .68), and these rates were not related to the effect of
valganciclovir on HHV-8 shedding (r  -0.16; P  .44).
No participant who was receiving either active study drug or
placebo experienced anemia, thrombocytopenia, or renal insuf-
ficiency. No serious adverse events were observed during the
study. One participant had a transient elevation in serum levels
of alanine aminotransferase during administration of placebo.
Three participants were neutropenic during the time they re-
ceived placebo (2 HIV-positive participants and 1 HIV-negative
participant), compared with 2 participants during the time they
received valganciclovir (both of whom were HIV-positive).
Among a subset of 22 participants who provided data on gastro-
intestinal symptoms during the study, nausea was reported by 2
HIV-positive participants while taking valganciclovir and re-
ported by 3 while taking placebo; abdominal cramps were re-
ported by 3 HIV-positive participants during the time they were
taking valganciclovir and reported by 4 during the time they
were taking placebo. Diarrhea was reported by 6 HIV-positive
participants and 1 HIV-negative participant while taking valgan-
Figure 2. Comparison of the rate of human herpesvirus–8 shedding in the oropharynx among participants who received valganciclovir and
participants who received placebo.
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ciclovir and reported by 3 HIV-positive participants and 1 HIV-
negative participant while taking placebo, though this person-
level difference was not significant (P  .50). Day-level or visit-
level comparison showed that participants reported a total of
132 days of diarrhea, including 9% of days on valganciclovir and
2% of days on placebo (P  .02).
DISCUSSION
We found that valganciclovir administered orally effectively in-
hibits mucosal HHV-8 replication. The frequency and with
which HHV-8 was detected in the oropharynx and the quantity
detected were significantly reduced during valganciclovir ther-
Figure 3. Oropharyngeal shedding of human herpesvirus– by day of study. Mean log10 copies of HHV-8 DNA detected in saliva is summarized for
all participants who provided data for each study day. Zero copies were assigned a log value of 0. A, All participants who received valganciclovir
followed by placebo (n  13). B, All participants who received placebo followed by valganciclovir (n  13). C, HIV-positive participants who received
valganciclovir followed by placebo (n  8). D, HIV-positive participants who received placebo followed by valganciclovir (n  8).
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apy. The antiviral effect was reasonably prompt and appeared to
be independent of the drug’s substantial reduction in CMV rep-
lication. HHV-8 replication resumed on discontinuation of the
drug, indicating the need to use daily dosing to achieve effective
virologic control. This study also corroborates previous findings
that oropharyngeal shedding of HHV-8 is frequent among HIV-
positive persons asymptomatically infected with HHV-8 (espe-
cially those with high CD4 T cell counts) [19, 22], as well as
asympotomatically infected men without HIV infection [18].
The role that direct antiviral chemotherapy will play in pre-
venting HHV-8 –associated infection or disease remains to be
determined. The reduced incidence of KS observed in the afore-
mentioned studies of HIV-positive persons treated with ganci-
clovir suggested that the prevention of KS with antiviral medi-
cations was possible. Although latent HHV-8 is the predominant
form of viral infection in KS tissue, HHV-8 replication is essen-
tial to the initiation or maintenance of HHV-8 –associated dis-
ease. Lytic HHV-8 replication is necessary for the persistence of
KS lesions [23, 24], and the detection of HHV-8 in plasma has
been associated with the subsequent development of KS in pro-
spective studies of patients with HIV infection [25–30]. Addi-
tionally, HHV-8 produces angiogenic and inflammatory factors
during lytic replication, including an interleukin-6 analogue and
a viral G-protein– coupled receptor [31]. These data suggest the
potential for antiviral medication to mitigate some of these viral
replication–related sequelae.
We felt it was important to establish the antiviral activity of
valganciclovir prior to embarking on a study to demonstrate its
clinical efficacy. Given the current expense of valganciclovir and
the potential toxicities associated with long-term use, its role in
the prevention of KS in areas where the condition is endemic
remains to be explored. One potential strategy would be inter-
mittent administration to persons predicted to be at high risk for
developing KS on the basis of previously described risk factors,
such as HHV-8 viremia [25–30], absence of neutralizing anti-
bodies to HHV-8 [32], or profound immunosuppression [33].
Alternatively, valganciclovir may be useful for the prevention of
KS in high-risk transplant patients, as it has been shown that it
can be used safely for the prevention of CMV disease in this
setting. Although lytic replication may play a role in some as-
pects of KS, antiviral therapy is not likely to be of benefit when
used as a single agent for the treatment of KS, as the role of
persistent viral replication after malignant transformation is less
clear [34].
Antiviral therapy may also be useful in the treatment of some
HHV-8 –related disease. For example, almost all cells infected
with HHV-8 in MCD harbor lytically replicating virus [35], and
the quantity of HHV-8 in the peripheral blood closely parallels
the acuity of disease [36]. The results of this randomized trial
lend support to our previous clinical observations documenting
reductions in HHV-8 viremia and concomitant clinical im-
provement among patients with MCD who received valganci-
clovir [13]. The amount of HHV-8 replication in patients with
PEL is intermediate between that in patients KS and that in pa-
tients with MCD, but evidence for an adjunctive role for antivi-
ral medication in the treatment of PEL offers hope that the treat-
ment of this high-mortality disease could be improved [37].
Studies to optimize the dose and duration of valganciclovir ther-
apy for patients with MCD and patients with PEL should be
undertaken.
Our study design was an efficient approach for defining the
antiviral activity of orally administered valganciclovir against
HHV-8 replication in vivo. However, this study design also had
a number of important limitations. First, the population was
highly selected, having been previously observed to have HHV-8
frequently detected in the oropharynx. Future studies using less-
selected patient populations and defining the antiviral effects in
other body sites should be pursued. Similarly, additional trials to
define the optimal dose for prevention of HHV-8 –associated
diseases are needed. Valganciclovir is initially administered at
900 mg twice per day for the treatment of cytomegalovirus (“in-
duction”), after which it is often reduced to 900 mg once per day
(“maintenance”). Given that the toxicity of valganciclovir is in
part dose related and that this study was an exploratory trial, we
elected to use the lower dose. It was gratifying that we were able
to demonstrate an effective antiviral effect with minimal toxic-
ity, suggesting the possibility of trials of longer duration that
might result in true clinical benefit. The observed reductions in
HHV-8 shedding were limited in both magnitude and duration.
It is unclear whether higher doses would have resulted in greater
efficacy, greater toxicity, or both.
In conclusion, to our knowledge valganciclovir is the first an-
tiviral agent shown to reduce HHV-8 replication in a random-
ized clinical trial, . Antiviral medications have been shown to be
useful in the prevention of other virus-associated malignancies,
including hepatocellular carcinoma [38] and posttransplant
lymphoproliferative disease [39]. The prevention of KS with val-
ganciclovir in persons judged to be at high risk on the basis of
immunosuppression and the presence of frequent and sustained
HHV-8 replication could be an important strategy in areas
where KS is endemic. Additional research is needed to define the
optimal use of antiviral drugs for persons infected with HHV-8,
but this study offers hope that the prevention of HHV-8 –asso-
ciated malignancies might be feasible.
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